Fusion Pharmaceuticals Inc. Research and Development Expense
Fusion Pharmaceuticals Inc. reported Research and Development Expense of $21.31 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2024-05-07
- Fusion Pharmaceuticals Inc. research and development expense for the quarter ending 2024-03-31 was $21.31M, a 34.23% increase year-over-year.
- Fusion Pharmaceuticals Inc. research and development expense for the quarter ending 2023-12-31 was $20.65M, a 17.27% increase year-over-year.
- Fusion Pharmaceuticals Inc. research and development expense for the quarter ending 2023-09-30 was $14.59M, a 11.88% decline year-over-year.
- Fusion Pharmaceuticals Inc. research and development expense for the quarter ending 2023-06-30 was $18.99M, a 57.29% increase year-over-year.
- Fusion Pharmaceuticals Inc. research and development expense for fiscal 2023 was $70.10M, a 19.03% increase from fiscal 2022.
- Fusion Pharmaceuticals Inc. research and development expense for fiscal 2022 was $58.90M, a 4.50% increase from fiscal 2021.
- Fusion Pharmaceuticals Inc. research and development expense for fiscal 2021 was $56.36M, a 227.83% increase from fiscal 2020.
- Fusion Pharmaceuticals Inc. research and development expense for fiscal 2020 was $17.19M, a 61.69% increase from fiscal 2019.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $21.31M 10-Q · filed 2024-05-07 | $41.96M derived: sum of 2 quarters · filed 2024-05-07 | $56.54M derived: sum of 3 quarters · filed 2024-05-07 | $75.54M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | $20.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $35.23M derived: sum of 2 quarters · filed 2024-03-20 | $54.23M derived: sum of 3 quarters · filed 2024-03-20 | $70.10M 10-K · filed 2024-03-20 |
| 2023-09-30 | $14.59M 10-Q · filed 2023-11-07 | $33.58M derived: sum of 2 quarters · filed 2023-11-07 | $49.46M 10-Q · filed 2023-11-07 | $67.06M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-06-30 | $18.99M 10-Q · filed 2023-08-08 | $34.87M 10-Q · filed 2023-08-08 | $52.48M derived: sum of 3 quarters · filed 2024-05-07 | $69.03M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-03-31 | $15.88M 10-Q · filed 2024-05-07 | $33.48M derived: sum of 2 quarters · filed 2024-05-07 | $50.03M derived: sum of 3 quarters · filed 2024-05-07 | $62.11M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $17.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $34.16M derived: sum of 2 quarters · filed 2024-03-20 | $46.23M derived: sum of 3 quarters · filed 2024-03-20 | $58.90M 10-K · filed 2024-03-20 |
| 2022-09-30 | $16.55M 10-Q · filed 2023-11-07 | $28.63M derived: sum of 2 quarters · filed 2023-11-07 | $41.29M 10-Q · filed 2023-11-07 | $53.10M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $12.08M 10-Q · filed 2023-08-08 | $24.74M 10-Q · filed 2023-08-08 | $36.55M derived: sum of 3 quarters · filed 2023-08-08 | $49.23M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $12.66M 10-Q · filed 2023-05-11 | $24.47M derived: sum of 2 quarters · filed 2023-05-11 | $37.16M derived: sum of 3 quarters · filed 2023-05-11 | $58.30M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $11.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $24.50M derived: sum of 2 quarters · filed 2023-03-16 | $45.64M derived: sum of 3 quarters · filed 2023-03-16 | $56.36M 10-K · filed 2023-03-16 |
| 2021-09-30 | $12.68M 10-Q · filed 2022-11-08 | $33.83M derived: sum of 2 quarters · filed 2022-11-08 | $44.55M 10-Q · filed 2022-11-08 | $49.51M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $21.15M 10-Q · filed 2022-08-09 | $31.86M 10-Q · filed 2022-08-09 | $36.82M derived: sum of 3 quarters · filed 2022-08-09 | $41.35M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $10.72M 10-Q · filed 2022-05-10 | $15.68M derived: sum of 2 quarters · filed 2022-05-10 | $20.20M derived: sum of 3 quarters · filed 2022-05-10 | $23.53M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $9.49M derived: sum of 2 quarters · filed 2022-03-17 | $12.81M derived: sum of 3 quarters · filed 2022-03-17 | $17.19M 10-K · filed 2022-03-17 |
| 2020-09-30 | $4.53M 10-Q · filed 2021-11-09 | $7.85M derived: sum of 2 quarters · filed 2021-11-09 | $12.23M 10-Q · filed 2021-11-09 | $15.65M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $3.33M 10-Q · filed 2021-08-10 | $7.70M 10-Q · filed 2021-08-10 | $11.12M derived: sum of 3 quarters · filed 2021-08-10 | $13.36M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $4.38M 10-Q · filed 2021-05-11 | $7.79M derived: sum of 2 quarters · filed 2021-05-11 | $10.03M derived: sum of 3 quarters · filed 2021-05-11 | $12.17M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $5.65M derived: sum of 2 quarters · filed 2021-03-25 | $7.79M derived: sum of 3 quarters · filed 2021-03-25 | $10.63M 10-K · filed 2021-03-25 |
| 2019-09-30 | $2.24M 10-Q · filed 2020-11-10 | $4.38M derived: sum of 2 quarters · filed 2020-11-10 | $7.22M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $2.14M 10-Q · filed 2020-08-11 | $4.98M 10-Q · filed 2020-08-11 |